News & Events about Iveric Bio Inc.
IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on January 3, 2023, the Company granted equity-based awards pursuant to the Companys 2019 Inducement Stock Incentive Plan to twelve newly-hired, non-executive employees. These inducement grants were approved by the Companys compensation and talent...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the Companys business strategy and in overseeing the development and...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug Application (NDA) for rolling review of avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of...
Business Wire
2 months ago
IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on December 1, 2022, the Company granted equity-based awards pursuant to the Companys 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees. These inducement grants were approved by the Companys compensation and talent...
Business Wire
2 months ago
IVERIC bio, Inc. (Nasdaq: ISEE) (the Company), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the...